| 1 |
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Frank Stephen Hodi et al. · New England Journal of Medicine
Open access |
5 Jun 2010 |
15,337 |
| 2 |
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne Louise Topalian et al. · New England Journal of Medicine
Open access |
14 Jun 2012 |
12,842 |
| 3 |
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei et al. · New England Journal of Medicine
Open access |
27 Sep 2015 |
9,557 |
| 4 |
Estimating the mean and variance from the median, range, and the size of a sample
Stela Pudar Hozo, Benjamin Djulbegović, Iztok Hozo · BMC Medical Research Methodology
Open access |
20 Apr 2005 |
9,308 |
| 5 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie Renee Brahmer et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,632 |
| 6 |
Radiomics: Images Are More than Pictures, They Are Data
Robert J. Gillies, Paul E. Kinahan, Hedvig Hricak · Radiology
Open access |
18 Nov 2015 |
8,616 |
| 7 |
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich, Srinivas Nagaraj · Nature reviews. Immunology
ReviewOpen access |
7 Feb 2009 |
6,796 |
| 8 |
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi et al. · New England Journal of Medicine
Open access |
16 Apr 2018 |
6,764 |
| 9 |
Radiomics: Extracting more information from medical images using advanced feature analysis
Philippe Lambin, Emmanuel Rios-Velazquez, Ralph T. H. Leijenaar et al. · European Journal of Cancer
Open access |
16 Jan 2012 |
6,202 |
| 10 |
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva Swarup Neelapu et al. · New England Journal of Medicine
Open access |
10 Dec 2017 |
6,098 |
| 11 |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky et al. · Autophagy
Open access2,467 authors |
2 Jan 2016 |
6,023 |
| 12 |
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria et al. · New England Journal of Medicine
Open access |
18 Nov 2017 |
5,475 |
| 13 |
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Hugo J.W.L. Aerts, Emmanuel Rios Velazquez, Ralph T. H. Leijenaar et al. · Nature Communications
Open access |
3 Jun 2014 |
5,287 |
| 14 |
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al. · New England Journal of Medicine
|
5 Jun 2011 |
4,523 |
| 15 |
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph David Khoury et al. · Leukemia
Open access |
22 Jun 2022 |
4,204 |
| 16 |
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Sarah C. Darby, Marianne Ewertz, Paul McGale et al. · New England Journal of Medicine
Open access |
13 Mar 2013 |
4,034 |
| 17 |
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al. · Transplantation and Cellular Therapy
Open access |
25 Dec 2018 |
3,663 |
| 18 |
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich, Suzanne Ostrand‐Rosenberg, Vincenzo Bronte · Nature reviews. Immunology
ReviewOpen access |
22 Mar 2012 |
3,573 |
| 19 |
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid et al. · New England Journal of Medicine
Open access |
2 Jun 2013 |
3,425 |
| 20 |
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg et al. · New England Journal of Medicine
Open access |
11 Jan 2017 |
3,307 |
| 21 |
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
Jay Scott Cooper, Thomas F. Pajak, Arlene A. Forastiere et al. · New England Journal of Medicine
|
5 May 2004 |
3,297 |
| 22 |
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Arlene A. Forastiere, Helmuth Goepfert, Moshe H Maor et al. · New England Journal of Medicine
Open access |
26 Nov 2003 |
3,192 |
| 23 |
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Suresh S. Ramalingam et al. · New England Journal of Medicine
Open access |
21 Nov 2019 |
2,933 |
| 24 |
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Gordon Henry Guyatt, Andrew David Oxman, Gunn Elisabeth Vist et al. · Journal of Clinical Epidemiology
|
24 Jan 2011 |
2,894 |
| 25 |
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al. · New England Journal of Medicine
Open access |
30 Sep 2012 |
2,838 |
| 26 |
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver A. Sartor, Johann Sebastian De Bono, Kim N. Chi et al. · New England Journal of Medicine
Open access |
23 Jun 2021 |
2,834 |
| 27 |
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
María E. Figueroa et al. · Cancer Cell
Open access |
Dec 2010 |
2,793 |
| 28 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
Roger Stupp et al. · JAMA
Open access |
19 Dec 2017 |
2,699 |
| 29 |
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al. · The Lancet Oncology
|
23 Mar 2015 |
2,696 |
| 30 |
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
Daniel Y. Wang et al. · JAMA Oncology
Open access |
18 Sep 2018 |
2,692 |
| 31 |
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology
Open access |
22 Feb 2009 |
2,681 |
| 32 |
Expanded encyclopaedias of DNA elements in the human and mouse genomes
Federico Abascal et al. · Nature
Open access566 authors |
29 Jul 2020 |
2,676 |
| 33 |
Macrophages as regulators of tumour immunity and immunotherapy
David Glenn DeNardo, Brian Ruffell · Nature reviews. Immunology
ReviewOpen access |
4 Feb 2019 |
2,661 |
| 34 |
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Paul Gerard Guy Richardson et al. · New England Journal of Medicine
Open access |
25 Jun 2003 |
2,656 |
| 35 |
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet
|
Oct 2006 |
2,626 |
| 36 |
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David Paul Carbone et al. · New England Journal of Medicine
Open access |
21 Jun 2017 |
2,602 |
| 37 |
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
Andy Trotti, A. D. Colevas, A. Setser et al. · Seminars in Radiation Oncology
|
Jul 2003 |
2,589 |
| 38 |
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Paul Gerard Guy Richardson et al. · New England Journal of Medicine
Open access |
15 Jun 2005 |
2,514 |
| 39 |
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Sattva Swarup Neelapu, Sudhakar Tummala, Partow Kebriaei et al. · Nature Reviews Clinical Oncology
ReviewOpen access |
19 Sep 2017 |
2,452 |
| 40 |
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Florian R. Greten, Lars Eckmann, Tim F. Greten et al. · Cell
Open access |
Aug 2004 |
2,437 |
| 41 |
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess et al. · CA A Cancer Journal for Clinicians
Open access |
13 Oct 2017 |
2,317 |
| 42 |
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
Frederick Lundry Locke et al. · The Lancet Oncology
Open access |
2 Dec 2018 |
2,307 |
| 43 |
Radiomics: the process and the challenges
Virendra Kumar, Yuhua Gu, Satrajit Basu et al. · Magnetic Resonance Imaging
Open access |
13 Aug 2012 |
2,294 |
| 44 |
The STATs of cancer — new molecular targets come of age
Hua Yu, Richard Jove · Nature reviews. Cancer
Review |
Feb 2004 |
2,294 |
| 45 |
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey Alan Sosman et al. · New England Journal of Medicine
Open access |
22 Feb 2012 |
2,170 |
| 46 |
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
Jonathan Kocarnik et al. · JAMA Oncology
Open access601 authors |
30 Dec 2021 |
2,100 |
| 47 |
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Andrea Bild, Guang Yao, Jeffrey T. Chang et al. · Nature
|
6 Nov 2005 |
2,080 |
| 48 |
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Ed Seto, Minoru Yoshida · Cold Spring Harbor Perspectives in Biology
Open access |
Apr 2014 |
2,048 |
| 49 |
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley et al. · The Lancet Oncology
Open access |
15 Jan 2015 |
2,047 |
| 50 |
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al. · New England Journal of Medicine
Open access |
14 Mar 2012 |
1,971 |